Skip to main navigation Skip to search Skip to main content

Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines

  • B. Yamout
  • , M. Al-Jumah
  • , M. A. Sahraian
  • , Y. Almalik
  • , J. Al Khaburi
  • , N. Shalaby
  • , S. Aljarallah
  • , S. Bohlega
  • , M. Dahdaleh
  • , A. Almahdawi
  • , S. J. Khoury
  • , S. Koussa
  • , E. Slassi
  • , S. Daoudi
  • , H. Aref
  • , S. Mrabet
  • , M. Zeineddine
  • , M. Zakaria
  • , J. Inshasi
  • , R. Gouider
  • R. Alroughani
  • Harley Street Medical Center
  • InterHealth Hospital
  • Tehran University of Medical Sciences
  • King Saud bin Abdulaziz University for Health Sciences
  • Royal Hospital Oman
  • Cairo University
  • King Saud University
  • King Faisal Specialist Hospital and Research Centre
  • Al Khalidi Hospital
  • Baghdad Medical City
  • American University of Beirut
  • Lebanese University
  • Cheikh Khalifa International University Hospital
  • Mouloud Mammeri University of Tizi-Ouzou
  • Ain Shams University
  • Université de Tunis El Manar
  • Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS)
  • Al-Amiri Hospital

Research output: Contribution to journal › Review article › peer-review

57 Scopus citations

Abstract

With evolving diagnostic criteria and the advent of new oral and parenteral therapies for Multiple Sclerosis (MS), most current diagnostic and treatment algorithms need revision and updating. The diagnosis of MS relies on incorporating clinical and paraclinical findings to prove dissemination in space and time and exclude alternative diseases that can explain the findings at hand. The differential diagnostic workup should be guided by clinical and laboratory red flags to avoid unnecessary tests. Appropriate selection of MS therapies is critical to maximize patient benefit. The current guidelines review the current diagnostic criteria for MS and the scientific evidence supporting treatment of acute relapses, radiologically isolated syndrome, clinically isolated syndrome, relapsing remitting MS, progressive MS, pediatric cases and pregnant women. The purpose of these guidelines is to provide practical recommendations and algorithms for the diagnosis and treatment of MS based on current scientific evidence and clinical experience.

Original languageEnglish
Article number105435
JournalMultiple Sclerosis and Related Disorders
Volume83
DOIs
StatePublished - Mar 2024

Keywords

  • Diagnosis
  • Disease-modifying therapies
  • Guidelines
  • Management
  • Multiple Sclerosis
  • Treatment

Fingerprint

Dive into the research topics of 'Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines'. Together they form a unique fingerprint.

Cite this